These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9748031)

  • 1. Early dopaminergic drug-induced hallucinations in parkinsonian patients.
    Goetz CG; Vogel C; Tanner CM; Stebbins GT
    Neurology; 1998 Sep; 51(3):811-4. PubMed ID: 9748031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
    Goetz CG; Wuu J; Curgian L; Leurgans S
    Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?
    Kataoka H; Sawa N; Sugie K; Ueno S
    J Neurol Sci; 2014 Dec; 347(1-2):361-3. PubMed ID: 25454646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
    Friedman JH; Agarwal P; Alcalay R; Black KJ; Chou KL; Cote L; Dayalu P; Frank S; Hartlein J; Hauser RA; Lang AE; Marsh L; Marshall F; Moskowitz C; Ravina B; Riley D; Sanchez-Ramos J; Simon DK; Simuni T; Sutton J; Tuite P; Weintraub D; Zesiewicz T
    Int J Neurosci; 2011 Aug; 121(8):472-6. PubMed ID: 21663381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.
    Merims D; Shabtai H; Korczyn AD; Peretz C; Weizman N; Giladi N
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1447-53. PubMed ID: 15480845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinations and sleep disturbances in Parkinson's disease.
    Kulisevsky J; Roldan E
    Neurology; 2004 Oct; 63(8 Suppl 3):S28-30. PubMed ID: 15505140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study.
    Williams DR; Lees AJ
    Lancet Neurol; 2005 Oct; 4(10):605-10. PubMed ID: 16168928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hallucinations in Parkinson's disease--a study of forty three patients.
    Gupta M; Singh G; Khwaja GA; Mehndiratta MM
    J Assoc Physicians India; 2004 Sep; 52():703-6. PubMed ID: 15839446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-induced hallucination and cerebral blood flow in Parkinson's disease.
    Okada K; Suyama N; Oguro H; Yamaguchi S; Kobayashi S
    J Neurol; 1999 May; 246(5):365-8. PubMed ID: 10399867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
    Comella CL; Tanner CM; Ristanovic RK
    Ann Neurol; 1993 Nov; 34(5):710-4. PubMed ID: 8239565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
    Rudolf J; Ghaemi M; Schmülling S
    Eur Psychiatry; 1999 Oct; 14(6):356-7. PubMed ID: 10572371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
    Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N
    Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic delusional hallucinatory psychosis in early-onset Parkinson's disease: drug-induced complication or sign of an idiopathic psychiatric illness?
    Cannas A; Spissu A; Floris GL; Saddi MV; Cossu G; Melis M; Tacconi P; Milia A; Mascia MM; Giagheddu M
    Neurol Sci; 2001 Feb; 22(1):53-4. PubMed ID: 11487198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.